SynthesisBrain and behavior2026
Multi-Trait Genetic Insights Into Schizophrenia Across Ancestries: Genome-Wide Association Meta-Analyses, Machine Learning, and Drug Repurposing Study.
Synthesis in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSchizophrenia is a psychiatric disorder characterized by a wide range of symptoms and a complex interplay between genetic and environmental factors. Despite advances in genomics, the genetic underpinnings of SC and its relationship with drug use remain poorly understood.
methodsThis study utilized genome-wide association data from 53,386 SC patients and 77,258 controls of mainly European ancestry, and 22,778 patients and 35,362 controls of mainly East Asian ancestry, alongside GWAS summary data for 23 types of drug use. Genetic correlation analysis was conducted using linkage disequilibrium score regression, followed by meta-analysis of genome-wide association studies across multiple traits related to SC. Independent risk loci were identified, and their biological significance was explored using molecular methodologies. Machine learning techniques were employed to develop predictive models for SC diagnosis, and drug repurposing opportunities were investigated.
resultsWe found significant genetic correlations between SC and drug use in both ancestries, uncovering 24 previously unidentified loci associated with SC. Through various analytical strategies, we highlighted novel genes linked to SC and developed diagnostic models. Drug repurposing analysis identified ten drug classes with potential therapeutic relevance for SC, including cannabinoid receptor antagonists, which have shown promise in alleviating symptoms.
conclusionOur findings reveal a common genetic foundation linking susceptibility to schizophrenia with drug use, providing new insights into the genetic architecture of SC across ancestries. The identification of novel loci and genes associated with SC enhances our understanding of its biological underpinnings and offers potential targets for therapeutic intervention. Additionally, our study opens avenues for drug repurposing as a promising strategy for SC treatment, underscoring the importance of integrating genetic and pharmacological research in psychiatry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.